Metahexamide
![]()  | |
| Names | |
|---|---|
| Preferred IUPAC name
 3-Amino-N-(cyclohexylcarbamoyl)-4-methylbenzene-1-sulfonamide  | |
| Identifiers | |
CAS Number  | 
  | 
3D model (JSmol)  | 
|
| ChEMBL | |
| ChemSpider | 
  | 
| ECHA InfoCard | 100.008.434 | 
| KEGG | 
  | 
PubChem CID  | 
|
| UNII | |
CompTox Dashboard (EPA)  | 
|
InChI 
  | |
SMILES 
  | |
| Properties | |
Chemical formula  | 
C14H21N3O3S | 
| Molar mass | 311.4 g/mol | 
| Pharmacology | |
| A10BB10 (WHO) | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). 
Infobox references  | |
Metahexamide (INN) is an anti-diabetic drug from the group of sulfonylureas. It is long-acting and belongs to the first-generation cyclohexyl-containing sulfonylureas. It was first described in 1959.[1]
References
- ↑ Moss JM, Delawter D (September 1959). "Metahexamide in diabetes therapy". Ann NY Acad Sci. 82 (2): 614–7. doi:10.1111/j.1749-6632.1959.tb44940.x. PMID 14424617.
 
| Calcium | 
  | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Potassium | 
  | ||||||||||||||||||||||||
| Sodium | 
  | ||||||||||||||||||||||||
| Chloride | 
  | ||||||||||||||||||||||||
| Others | 
  | ||||||||||||||||||||||||
See also: Receptor/signaling modulators • Transient receptor potential channel modulators  | |||||||||||||||||||||||||
    This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.
